Skin Care Education

Xeomin

A botulinum toxin type A neuromodulator made by Merz, distinguished by its naked formulation that contains only the active toxin without the accessory proteins found in other neuromodulator products.

What Is Xeomin?

Xeomin is a brand of botulinum toxin type A made by Merz Aesthetics. Like other neuromodulators in this category, it temporarily blocks the nerve signals that cause muscles to contract, reducing the strength of muscle activity in the treated area and allowing expression lines to smooth out. It is approved for aesthetic use for the treatment of moderate to severe frown lines between the brows, and is used by clinicians across the same range of aesthetic applications as other neuromodulators including forehead lines, crow’s feet, jaw slimming, brow lifting, and neck bands.

What distinguishes Xeomin from Botox and Dysport is its formulation. Xeomin is described as a naked toxin because it contains only the pure botulinum toxin type A molecule without the complexing proteins that are present in other botulinum toxin products. These accessory proteins are not part of the active mechanism of the toxin but are present in the formulations of other products. Merz describes Xeomin’s purity as potentially reducing the likelihood of the body developing antibodies to the accessory proteins, which in theory could contribute to reduced responsiveness to treatment over time with other products.

The clinical relevance of this formulation difference is a matter of ongoing discussion in aesthetic medicine. In practice, most providers find Xeomin produces comparable results to other botulinum toxin type A products when used at appropriate doses, and the theoretical antibody advantage has not been definitively demonstrated to be clinically meaningful in the general aesthetic population. The choice between Xeomin and other brands remains primarily a provider preference.

What to Expect

Xeomin treatment follows the standard process for all neuromodulator injections. A series of small injections are placed precisely into the targeted muscles using a fine needle. The procedure takes 10 to 20 minutes and most people describe the sensation as a mild pinch at each injection site. Numbing cream is not usually needed. There is no significant downtime.

The effect begins to appear within two to five days and is fully established at two weeks. A review at two weeks is standard to assess the result and address any areas that may benefit from adjustment. The effect typically lasts three to four months, after which muscle activity gradually returns to normal.

One practical consideration with Xeomin is that, unlike Botox and Dysport, it does not contain preservatives and requires refrigeration until use, then should be used within a certain period after reconstitution. This is a handling consideration for the clinic rather than the client, but it is worth being aware of as a characteristic of the product.

Who It’s For and Results

Xeomin is suited to the same range of candidates as other neuromodulator treatments: adults wanting to reduce expression lines, prevent their deepening, or address other muscle-related concerns. It is also sometimes considered for those who feel they may have developed reduced responsiveness to other botulinum toxin products over time, given the theoretical argument about accessory protein antibodies, though this is not universally supported by clinical evidence.

Results are a natural-looking softening of expression lines with preserved facial movement. As with all neuromodulators, the quality of the result depends primarily on the provider’s skill, experience, and the appropriateness of the dosing and placement rather than on which specific brand is used.

Regular maintenance treatments every three to four months sustain the result. The effect and duration of Xeomin are broadly comparable to other botulinum toxin type A products when used at equivalent therapeutic doses.

Frequently Asked Questions: Xeomin

The main difference is in the formulation. Xeomin contains only the pure botulinum toxin type A molecule without the complexing proteins present in Botox. This gives Xeomin its reputation as a naked or pure toxin. The clinical significance of this difference is debated, but the theoretical rationale is that the absence of accessory proteins may reduce the risk of antibody development that could diminish responsiveness to treatment over time. In terms of mechanism, onset, duration, and clinical results, Xeomin and Botox are broadly comparable when used at appropriate doses by experienced providers.

This is one of the clinical situations where Xeomin is sometimes considered. The theory is that long-term exposure to the accessory proteins in other botulinum toxin products can lead to the development of antibodies that reduce the effectiveness of those products over time. Switching to Xeomin, which lacks these proteins, may in theory restore responsiveness. The evidence for this is limited and the phenomenon of true resistance to botulinum toxin from antibody formation is relatively rare in the aesthetic population, but Xeomin is a reasonable option to try in cases where a clear reduction in response to other products is observed.

Xeomin typically lasts three to four months, comparable to other botulinum toxin type A products. Individual variation means some people experience results lasting closer to three months and others closer to five. The area treated, the amount used, and the individual’s metabolism all influence duration. Regular retreatment before the effect fully wears off maintains a consistent result, and with consistent treatment over time many people find their results gradually last a little longer as the treated muscles reduce slightly in bulk.

Not in a straightforward sense. All botulinum toxin type A products used in aesthetic practice have strong safety records at the doses used. The naked formulation of Xeomin is not associated with a meaningfully different safety profile for the client compared to other products. The theoretical reduction in antibody risk is a long-term consideration related to treatment response rather than an immediate safety advantage. For practical safety, the most important factors remain the same regardless of which brand is used: choosing a qualified and experienced provider, appropriate dosing, and correct placement.